--- title: "IMVT-1402 (Imeroprubart): The Albumin-Sparing FcRn Blocker Built to Replace Batoclimab (July 27, 2026) | PepTracker Pro Blog" description: "Yesterday we told the story of batoclimab - the FcRn blocker that worked in Phase 3 and was deliberately shelved. Today, meet its replacement. IMVT-1402 (imeroprubart) was engineered to lower IgG just as deeply as batoclimab while sparing the serum albumin and LDL cholesterol that sank its predecessor. It is now Immunovant's lead asset, with registrational Graves' and myasthenia readouts due in 2027." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "Article", "headline": "IMVT-1402 (Imeroprubart): The Albumin-Sparing FcRn Blocker Built to Replace Batoclimab (July 27, 2026)", "description": "Yesterday we told the story of batoclimab - the FcRn blocker that worked in Phase 3 and was deliberately shelved. Today, meet its replacement. IMVT-1402 (imeroprubart) was engineered to lower IgG just as deeply as batoclimab while sparing the serum albumin and LDL cholesterol that sank its predecessor. It is now Immunovant's lead asset, with registrational Graves' and myasthenia readouts due in 2027.", "datePublished": "2026-07-27", "dateModified": "2026-07-27", "author": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "publisher": { "@type": "Organization", "name": "PepTracker Pro", "logo": { "@type": "ImageObject", "url": "https://peptrackerpro.com/favicon.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://peptrackerpro.com/blog/imvt-1402-imeroprubart-hl161ans-albumin-sparing-fcrn-blocker-batoclimab-successor-myasthenia-graves-rheumatoid-arthritis-july-27-2026" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://peptrackerpro.com/blog" }, { "@type": "ListItem", "position": 3, "name": "IMVT-1402 (Imeroprubart): The Albumin-Sparing FcRn Blocker Built to Replace Batoclimab (July 27, 2026)", "item": "https://peptrackerpro.com/blog/imvt-1402-imeroprubart-hl161ans-albumin-sparing-fcrn-blocker-batoclimab-successor-myasthenia-graves-rheumatoid-arthritis-july-27-2026" } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Blog](/blog)/ IMVT-1402 (Imeroprubart): The Albumin-Sparing FcRn Blocker Built to Replace Batoclimab (July 27, 2026) Research & Compounds Research & Compounds # IMVT-1402 (Imeroprubart): The Albumin-Sparing FcRn Blocker Built to Replace Batoclimab (July 27, 2026) PepTracker Pro Research Team July 27, 2026 8 min read ## Table of Contents - [The successor batoclimab was shelved for](#section-0) - [Same target, one big fix](#section-1) - [The Phase 1 data that made the case](#section-2) - [A deliberately broad program](#section-3) - [Early efficacy: difficult-to-treat rheumatoid arthritis](#section-4) - [What's coming in 2027](#section-5) - [How it fits the class - and the standing caution](#section-6) ## The successor batoclimab was shelved for Yesterday's post ended on a twist: batoclimab hit its Phase 3 myasthenia gravis endpoint, posted best-in-class Graves' disease remission data, and was then deliberately not filed for approval. The reason was a re-engineered follow-on, and this is it. IMVT-1402 - international nonproprietary name imeroprubart, originally HL161ANS - is Immunovant/Roivant's next-generation anti-FcRn antibody, built to keep everything batoclimab did well while fixing the one thing it did badly. After batoclimab's Phase 3 thyroid eye disease trials failed in April 2026, Immunovant discontinued batoclimab development entirely and made IMVT-1402 its lead asset. It is now the centerpiece of one of the broadest late-stage autoimmune programs in the FcRn class. ## Same target, one big fix IMVT-1402 is a fully human, full-length IgG1 monoclonal antibody that binds the neonatal Fc receptor (FcRn) at its IgG-binding site - structurally in the same family as batoclimab, not efgartigimod's engineered Fc fragment. Occupy FcRn and you block the recycling that normally rescues IgG from lysosomal degradation, so unrescued IgG - including pathogenic autoantibodies - is destroyed and total IgG falls, while IgM, IgA and complement are spared. That is standard FcRn pharmacology. The innovation is what IMVT-1402 does not do. Because FcRn also recycles serum albumin, first-generation blockers like batoclimab reproducibly lowered serum albumin and raised LDL and total cholesterol - an on-target 'tax' baked into the mechanism. IMVT-1402 was purpose-engineered to decouple those effects: to lower IgG just as deeply while leaving albumin recycling and lipids largely alone. ## The Phase 1 data that made the case The albumin-sparing claim is not marketing - it showed up cleanly in Phase 1. In healthy volunteers, four once-weekly 300 mg subcutaneous doses of IMVT-1402 cut mean total IgG by about 63%, with no decrease in serum albumin below baseline and no increase in LDL-C above baseline. Stepping up to four weekly 600 mg doses reduced IgG by roughly 74% - about 80% at steady state after six to eight weeks - with the same clean albumin and lipid picture. In other words, IMVT-1402 matched or beat batoclimab's IgG-lowering potency without reproducing its signature laboratory liability. That dissociation is the whole thesis, and it is why Roivant framed the results as confirming best-in-class potential. ## A deliberately broad program Confidence built by batoclimab's clinical proof-of-concept let Immunovant fan IMVT-1402 out across roughly six autoimmune indications at once. The company is running potentially registrational trials in Graves' disease, difficult-to-treat rheumatoid arthritis, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjogren's disease, plus a proof-of-concept study in cutaneous lupus erythematosus. The logic is platform-level: if you have an FcRn antibody that lowers IgG deeply, self-injects at home, and does not tax albumin or lipids, it becomes plausible to test across the whole landscape of IgG-mediated autoimmunity rather than one disease at a time. ## Early efficacy: difficult-to-treat rheumatoid arthritis The first real efficacy signal outside myasthenia came from a hard population - heavily pretreated, difficult-to-treat rheumatoid arthritis, often with elevated ACPA autoantibodies, where deeper IgG lowering is a rational bet. Preliminary Week 16 data showed ACR20/ACR50/ACR70 response rates of roughly 72.7%, 54.5% and 35.8%. Those are early, open-label-style numbers, so the important caveat is that a randomized, placebo-controlled Period 2 is designed to test whether the response holds up, with topline data expected in the second half of 2026. Still, an ACR70 above one-third in refractory RA is the kind of signal that justifies a registrational push. ## What's coming in 2027 The events that will actually define IMVT-1402 are the potentially registrational Phase 3 readouts. The generalized myasthenia gravis study (for example NCT07039916) is a multicenter, randomized, double-blind, placebo-controlled trial with about 26 weeks of once-weekly subcutaneous treatment. Graves' disease - a flagship indication, chosen because batoclimab flashed drug-free remission there by lowering TSHR autoantibodies - is running in parallel (for example NCT07286006). Topline data from both the Graves' and myasthenia registrational trials is expected in calendar year 2027. Those readouts will show whether the albumin-sparing design translates into the same efficacy batoclimab delivered, now with a cleaner tolerability story. ## How it fits the class - and the standing caution Placed beside its peers, IMVT-1402 is the 'second-generation' entry in a class that reached the same target four different ways: efgartigimod (Fc fragment, cyclic infusion or SC), nipocalimab (aglycosylated IgG1, IV maintenance), rozanolixizumab (IgG4, subcutaneous cycles) and batoclimab (fully human IgG1, self-injected). IMVT-1402 keeps batoclimab's convenient at-home autoinjector while engineering out the albumin and lipid effects - the class trying to perfect itself. Two honest caveats remain. First, FcRn blockade does not help every antibody-mediated disease; batoclimab failed in thyroid eye disease and rozanolixizumab failed in CIDP, so IMVT-1402's six-indication breadth is a hypothesis, not a result. Second, the standing rule for the whole class applies here too: IMVT-1402 is investigational and prescription-only within trials, so any 'IMVT-1402', 'imeroprubart' or 'HL161ANS' offered by a research-chemical vendor is unverified and should not be used. Ready to track your peptide research? [Open PepTracker Pro](https://app.peptrackerpro.com) PepTracker Pro Research Team The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges. ## Citations 1. \[1\] Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn - Immunovant [Source](https://www.immunovant.com/investors/news-events/press-releases/detail/43/immunovant-announces-imvt-1402-a-next-generation-anti-fcrn) 2. \[2\] Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential - Roivant Sciences [Source](https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-imvt-1402-initial-600-mg-mad-results/) 3. \[3\] Immunovant (NASDAQ: IMVT) shifts to IMVT-1402 with broad late-stage autoimmune program - 10-K filing summary [Source](https://www.stocktitan.net/sec-filings/IMVT/10-k-immunovant-inc-files-annual-report-3714bb3d4535.html) 4. \[4\] IMVT-1402 Shows Strong Results in Rheumatoid Arthritis - AllSci [Source](https://allsci.com/news/clinical-trials/immunovant-posts-hopeful-data-for-fcrn-inhibitor-in-rheumatoid-arthritis-post-batoclimab-failure/) 5. \[5\] Phase 3 Study of IMVT-1402 in Generalized Myasthenia Gravis (NCT07039916) - UCSF Clinical Trials [Source](https://clinicaltrials.ucsf.edu/trial/NCT07039916) 6. \[6\] IMVT-1402 in Adult Participants With Graves' Disease (NCT07286006) - UCSF Clinical Trials [Source](https://clinicaltrials.ucsf.edu/trial/NCT07286006) **Disclaimer:** This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. [Read full research disclaimer →](/research-disclaimer) ## Related Articles [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/nipocalimab-imaavy-m281-fcrn-blocker-aglycosylated-antibody-myasthenia-gravis-sjogrens-hdfn-waiha-vivacity-dahlias-unity-july-24-2026) Research & Compounds [ ### Nipocalimab (Imaavy): The FcRn Blocker That Went Everywhere - From Myasthenia Gravis to the Womb (July 24, 2026) ](/blog/nipocalimab-imaavy-m281-fcrn-blocker-aglycosylated-antibody-myasthenia-gravis-sjogrens-hdfn-waiha-vivacity-dahlias-unity-july-24-2026) A day after efgartigimod, meet the other FcRn blocker. Nipocalimab uses the same trick - stop the receptor that recycles your antibodies - but as a full antibody, dosed continuously, and pushed into places no rival has gone: rheumatology, hematology, and even pregnancy. PepTracker Pro Team July 24, 2026 8 min read nipocalimabnipocalimab-aahuM281 [Read](/blog/nipocalimab-imaavy-m281-fcrn-blocker-aglycosylated-antibody-myasthenia-gravis-sjogrens-hdfn-waiha-vivacity-dahlias-unity-july-24-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/rozanolixizumab-rystiggo-ucb7665-fcrn-blocker-subcutaneous-igg4-myasthenia-gravis-musk-cidp-mycaring-july-25-2026) Research & Compounds [ ### Rozanolixizumab (Rystiggo): The Subcutaneous FcRn Blocker That Reached Both Myasthenia Serotypes First (July 25, 2026) ](/blog/rozanolixizumab-rystiggo-ucb7665-fcrn-blocker-subcutaneous-igg4-myasthenia-gravis-musk-cidp-mycaring-july-25-2026) Two days after efgartigimod and one after nipocalimab, meet the third FcRn blocker. Rozanolixizumab uses the same trick - stop the receptor that recycles your antibodies - but delivered under the skin, in cycles, and it was the first drug approved to cover both the AChR- and MuSK-antibody myasthenia serotypes. It's also an honest lesson in the mechanism's limits: it failed in CIDP. PepTracker Pro Team July 25, 2026 8 min read rozanolixizumabrozanolixizumab-noliUCB7665 [Read](/blog/rozanolixizumab-rystiggo-ucb7665-fcrn-blocker-subcutaneous-igg4-myasthenia-gravis-musk-cidp-mycaring-july-25-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/batoclimab-imvt-1401-rvt-1401-hbm9161-fcrn-blocker-self-injected-myasthenia-cidp-graves-imvt-1402-july-26-2026) Research & Compounds [ ### Batoclimab (IMVT-1401): The FcRn Blocker That Worked in Phase 3 - and Was Deliberately Not Filed (July 26, 2026) ](/blog/batoclimab-imvt-1401-rvt-1401-hbm9161-fcrn-blocker-self-injected-myasthenia-cidp-graves-imvt-1402-july-26-2026) Three days into the FcRn series we've met three approved blockers. Batoclimab is the fourth - and the odd one out: it hit its Phase 3 myasthenia endpoint, posted best-in-class Graves' remission data, and was then deliberately shelved in favor of a re-engineered successor. Here's why the drug that worked never got filed. PepTracker Pro Team July 26, 2026 8 min read batoclimabIMVT-1401RVT-1401 [Read](/blog/batoclimab-imvt-1401-rvt-1401-hbm9161-fcrn-blocker-self-injected-myasthenia-cidp-graves-imvt-1402-july-26-2026) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.